Hyperuricemia and gout: A reign of complacency

Cleveland Clinic Journal of Medicine

Volumn 69, Issue 8, 2002, Pages 589-593

  Mandell, Brian F ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; BENZBROMARONE; CARRIER PROTEIN; COLCHICINE; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; OXIPURINOL; URATE; URATE OXIDASE; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; DRUG SYNTHESIS; EDITORIAL; GENETIC HETEROGENEITY; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; INDIVIDUALIZATION; INTRACELLULAR TRANSPORT; KIDNEY CLEARANCE; KIDNEY FAILURE; KIDNEY PROXIMAL TUBULE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; RAT; SYNDROME X; URIC ACID BLOOD LEVEL;

EID: 0036685131     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.69.8.589     Document Type: Editorial

References (8)

1. Hyperuricemia: Treat or not treat?
2. Functional reconstitution, membrane targeting genomic structure, and chromosomal localization of a human urate transporter
3. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease
4. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism
5. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout
6. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?
7. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout
8. Efficacy and safety of desensitization to allopurinol following cutaneous reactions